-
Je něco špatně v tomto záznamu ?
Role of Metoprolol Succinate in the Treatment of Heart Failure and Atrial Fibrillation: A Systematic Review
D. Vinereanu, J. Spinar, A. Pathak, D. Kozlowski,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, systematický přehled
- MeSH
- alfa-1-adrenergní receptory - antagonisté terapeutické užití MeSH
- beta blokátory terapeutické užití MeSH
- fibrilace síní farmakoterapie MeSH
- lidé MeSH
- metoprolol terapeutické užití MeSH
- srdeční selhání farmakoterapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- systematický přehled MeSH
BACKGROUND: Beta-blockers are one of the most important classes of cardiovascular agents and have been considered a cornerstone therapy in heart diseases, such as heart failure (HF) and atrial fibrillation (AF). Among different beta-blockers, metoprolol is a selective beta1-adrenergic antagonist, which has been extensively used since the 1970s. AREAS OF UNCERTAINTY: Although current guidelines include recommendations for the use of controlled-release metoprolol succinate in specific HF and AF indications, and despite extensive clinical experience with metoprolol, comparative evidence on the use of metoprolol succinate compared with other beta-blockers in these indications is limited. DATA SOURCES: We systematically reviewed the data from head-to-head studies directly comparing this compound with other beta-blockers in the treatment of HF or AF. Only clinical trials and observational studies were considered; no other limits were applied. The quality and relevance of retrieved articles were reviewed. RESULTS: A total of 18 articles of the 353 articles identified were selected for inclusion; 12 HF articles and 6 for AF. Additional references were identified from the bibliographies of retrieved articles. The studies show that oral prophylaxis with an appropriate dose of metoprolol may reduce new incidents of AF in high-risk patients. Furthermore, metoprolol succinate is associated with significant mortality and morbidity benefits in the treatment of HF. CONCLUSIONS: Despite the introduction of newer beta-blockers with differing clinical characteristics since its introduction, metoprolol succinate remains a useful drug in both HF and AF.
Department of Cardiology and Electrotherapy Medical University of Gdansk Gdansk Poland
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20028421
- 003
- CZ-PrNML
- 005
- 20210114153821.0
- 007
- ta
- 008
- 210105s2020 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1097/MJT.0000000000001043 $2 doi
- 035 __
- $a (PubMed)31385823
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Vinereanu, Dragos $u Department of Cardiology, Emergency Hospital, University of Medicine and Pharmacy Carol Davila, Bucharest, Romania.
- 245 10
- $a Role of Metoprolol Succinate in the Treatment of Heart Failure and Atrial Fibrillation: A Systematic Review / $c D. Vinereanu, J. Spinar, A. Pathak, D. Kozlowski,
- 520 9_
- $a BACKGROUND: Beta-blockers are one of the most important classes of cardiovascular agents and have been considered a cornerstone therapy in heart diseases, such as heart failure (HF) and atrial fibrillation (AF). Among different beta-blockers, metoprolol is a selective beta1-adrenergic antagonist, which has been extensively used since the 1970s. AREAS OF UNCERTAINTY: Although current guidelines include recommendations for the use of controlled-release metoprolol succinate in specific HF and AF indications, and despite extensive clinical experience with metoprolol, comparative evidence on the use of metoprolol succinate compared with other beta-blockers in these indications is limited. DATA SOURCES: We systematically reviewed the data from head-to-head studies directly comparing this compound with other beta-blockers in the treatment of HF or AF. Only clinical trials and observational studies were considered; no other limits were applied. The quality and relevance of retrieved articles were reviewed. RESULTS: A total of 18 articles of the 353 articles identified were selected for inclusion; 12 HF articles and 6 for AF. Additional references were identified from the bibliographies of retrieved articles. The studies show that oral prophylaxis with an appropriate dose of metoprolol may reduce new incidents of AF in high-risk patients. Furthermore, metoprolol succinate is associated with significant mortality and morbidity benefits in the treatment of HF. CONCLUSIONS: Despite the introduction of newer beta-blockers with differing clinical characteristics since its introduction, metoprolol succinate remains a useful drug in both HF and AF.
- 650 _2
- $a alfa-1-adrenergní receptory - antagonisté $x terapeutické užití $7 D058668
- 650 _2
- $a beta blokátory $x terapeutické užití $7 D000319
- 650 _2
- $a fibrilace síní $x farmakoterapie $7 D001281
- 650 _2
- $a srdeční selhání $x farmakoterapie $7 D006333
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a metoprolol $x terapeutické užití $7 D008790
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a systematický přehled $7 D000078182
- 700 1_
- $a Spinar, Jindrich $u Department of Internal Cardiology Medicine, Faculty Hospital Brno, Faculty of Medicine, Masaryk University, Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital, Brno, Czech Republic.
- 700 1_
- $a Pathak, Atul $u Department of Cardiology, Clinique Pasteur, Toulouse, France.
- 700 1_
- $a Kozlowski, Dariusz $u Department of Cardiology and Electrotherapy, Medical University of Gdansk, Gdansk, Poland.
- 773 0_
- $w MED00179772 $t American journal of therapeutics $x 1536-3686 $g Roč. 27, č. 2 (2020), s. e183-e193
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31385823 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20210114153818 $b ABA008
- 999 __
- $a ok $b bmc $g 1608756 $s 1119601
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 27 $c 2 $d e183-e193 $e - $i 1536-3686 $m American journal of therapeutics $n Am J Ther $x MED00179772
- LZP __
- $a Pubmed-20210105